Eloxx Pharmaceuticals, Inc. (ELOX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29014R2022

Price
12.75 USD
Market cap
51.46 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Eloxx Pharmaceuticals, Inc. financials

Fiscal year2025
Revenue0.00 USD
Operating income-6.44 m USD
EBIT-6.00 m USD
Net income-6.00 m USD
Diluted EPS – continuing operations-0.49 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.